Trade name of the drug – IRS 19
International nonproprietary name: bacterial lysates mixture: S.pneumoniae, type I, II, III, V, VIII, XII + Haemophilus influenzae, type B + Klebsiella pneumoniae ss pneumoniae + Staphylococcus aureus ss aureus + Acinetobacter calcoaceticus + Moraxella catarrhalis + Neisseria subflava + Neisseria perflava + S.pyogenes group A + S.dysgalactiae group C + Enterococcus faecium + Enterococcus faecalis + S.group G].
Dosage form: nasal spray
Assignment.Prevention of chronic diseases of the upper respiratory tract and bronchi. Treatment of acute and chronic diseases of the upper respiratory tract and bronchi, such as rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis, and others. Restoring local immunity after an influenza and other viral infections. Preparations for planned surgery at the ENT-organs and in the postoperative period. IRS 19 can be assigned to both adults and children from 3 months of age.
Hypersensitivity to the drug or its components in history. IRS 19 should not be administered to patients with autoimmune diseases.
Use during pregnancy.
There is no sufficient data on the potential teratogenic or toxic effects on the fetus during pregnancy, so the use of the drug during pregnancy is not recommended.
Dosage and administration.
The drug is used intranasally by aerosol administration of one dose (1 dose = 1 short pressure sprayer).
In order to prevent adults and children from 3 months. 1 dose in each nostril 2 times a day for 2 weeks. (To start a course of treatment is recommended for 2-3 weeks before the expected rise of morbidity).
For the treatment of acute and chronic diseases of the upper respiratory tract and bronchi:
children from 3 months. up to 3 years and 1 dose in each nostril 2 times a day, after a preliminary release of mucous discharge, until the disappearance of symptoms of the infection.Children older than 3 years and adults: 1 dose in each nostril 2 to 5 times a day until the disappearance of symptoms of the infection.
To restore local immunity of children and adults after suffering flu and other respiratory viral infections and 1 dose in each nostril 2 times a day for 2 weeks.
In preparation for the planned surgery on the upper respiratory tract and in the postoperative period in adults and children 1 dose in each nostril 2 times a day for 2 weeks. (To start a course of treatment is recommended for 1 week before the expected surgery).
Early treatment can take place a short-term increase in sneezing and nasal discharge. If these reactions will take a severe course, reduce the frequency of administration of the drug or to cancel it.
May include the following side effects such as related and unrelated to the action of the drug.
Skin reactions: In rare cases, there may be hypersensitivity reactions (urticaria, angioedema) and erythema -like and eczema-like skin reaction.
From the upper respiratory tract and the respiratory system: rarely - asthma and cough.
In rare cases, early treatment can be observed: fever (≥39 ° C), nausea, vomiting, abdominal pain, diarrhea, nasopharyngitis, sinusitis, laryngitis, bronchitis.
Described isolated cases of thrombocytopenic purpura, and erythema nodosum.
Early treatment rarely possible increase in body temperature (≥ 39 ° C). In this case, treatment should be discontinued. In patients with asthma may cause asthma attacks. In this case, it is recommended to stop treatment or take drugs of this class in the future.
Storage and transportation conditions.
In the upright position at a temperature above 25 ° C, do not freeze.
Conditions of supply of pharmacies. Without recipe.